Group 1: Event Details - The company will participate in the "2023 Hebei Listed Companies Investor Collective Reception Day" [1] - The event will be held online on May 30, 2023, from 15:40 to 17:00 [1] - Investors can join via the "Panjing Roadshow" website, WeChat, or the Panjing Roadshow APP [1] Group 2: Communication Focus - Company executives will discuss the 2022 annual performance, corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [1] - The event aims to enhance interaction and communication with investors [1] Group 3: Assurance of Information - The company and its board guarantee the authenticity, accuracy, and completeness of the disclosed information, with no false records or significant omissions [1]

证券代码： 300869 证券简称：康泰医学 康泰医学系统(秦皇岛)股份有限公司投资者关系活动记录表 编号：202305001 您好，公司将严格按照相关规则披露定期报告，敬请关注公司公告， 感谢关注。 6、公司有没有人工智能技术储备 | 投资者关系活动类 | 特定对象调研 分析师会议 □ □ | | --- | --- | | 别 | 业绩说明会 □ 媒体采访 √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 投资者网上提问 | | 员姓名 | | | 时间 | 2023 年 5 月 18 日 (周四) 下午 15:30~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人员 | 1、董事长胡坤 | | 姓名 | 2、董事、总经理杨志山 | | | 3、董事、董事会秘书、财务总监郑敏 | | | 4、独立董事李华 | | | 5、保荐代表人孙泉 | | | 投资者提出的问题及公司回复情况 ...

证券代码：300869 证券简称：康泰医学 公告编号：2023-036 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 为充分尊重投资者，提升交流的针对性，现就公司 2022 年度业绩网上说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 05 月 17 日(星期三)15:30 前访问 http://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面进行提问。公司将在 2022 年度业绩说明会上，对投资 者普遍关注的问题进行回答。欢迎广大投资者积极参与本次业绩说明会。 特此公告。 康泰医学系统(秦皇岛)股份有限公司董事会 2023 年 5 月 15 日 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康泰医学系统(秦皇岛)股份有限公司（以下简称"公司"）2022 年年度报告 全文及其摘要已于 2023 年 4 月 27 日刊登于创业板信息披露媒体（巨潮资讯网 http://www.cninfo.com.cn）。为使投资者进一步了解公 ...

Financial Performance - The company's operating revenue for 2022 was ¥712,114,538.93, a decrease of 21.63% compared to ¥908,712,161.62 in 2021[17] - The net profit attributable to shareholders for 2022 was ¥196,202,558.53, down 44.32% from ¥352,353,389.50 in the previous year[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥144,688,613.92, a decline of 57.80% compared to ¥342,894,661.79 in 2021[17] - The basic earnings per share for 2022 were ¥0.49, down 44.32% from ¥0.88 in the previous year[17] - The weighted average return on net assets was 10.54%, a decrease of 10.36% from 20.90% in 2021[17] - The total operating revenue for 2022 was CNY 712.11 million, a decrease of 21.63% compared to CNY 908.71 million in 2021[106] - Revenue from the medical device sector was CNY 708.68 million, accounting for 99.52% of total revenue, also down by 21.68% from CNY 904.84 million in 2021[107] - The blood oxygen product line generated CNY 337.50 million in revenue, representing 47.39% of total revenue, a decline of 26.83% from CNY 461.26 million in 2021[107] - The company reported a significant revenue decline in the Northeast region by 73.15%, while the North China region saw an increase of 128.72%[107] Cash Flow and Investments - The net cash flow from operating activities increased significantly to ¥103,656,852.33, a rise of 2,130.42% from ¥4,647,412.40 in 2021[17] - Total cash inflow from operating activities decreased by 23.00% to ¥796,938,560.84 compared to ¥1,034,963,046.58 in the previous year[146] - Total cash outflow from operating activities decreased by 32.71% to ¥693,281,708.51 compared to ¥1,030,315,634.18 in the previous year[146] - Total cash inflow from financing activities increased by 90.67% to ¥1,744,977,357.32 compared to ¥915,196,350.00 in the previous year[146] - Net cash flow from financing activities increased by 571.77% to ¥781,337,905.36 compared to -¥165,617,705.13 in the previous year[146] - Cash and cash equivalents increased by 467.61% to ¥788,750,705.52 compared to -¥214,564,479.07 in the previous year[146] - The company issued convertible bonds, contributing to a significant increase in cash inflow from financing activities[149] - The total investment amount for the reporting period was CNY 136,134,028.07, representing an increase of 28.05% compared to the previous year's investment of CNY 106,310,458.98[160] Market Position and Industry Trends - The medical device market in China reached approximately ¥958.2 billion in 2022, with a compound annual growth rate of about 17.5% over the past seven years[30] - The company is positioned in a rapidly growing industry, with expectations of a compound annual growth rate of 14.41% over the next five years, potentially exceeding ¥1 trillion by 2025[31] - The global medical device market was valued at approximately $50.43 billion in 2021, with a projected growth to $53.28 billion in 2022[27] - The company operates in a competitive landscape where developed countries hold approximately 79.5% of the global market share, while developing countries like China account for about 19%[28] - The aging population and increasing health demands are expected to drive long-term growth in the medical device industry[64] Research and Development - R&D expenses for the year were 93.25 million yuan, an increase of 41.16% year-on-year, accounting for 13.1% of operating revenue[81] - The company has a stable R&D team of 606 people, accounting for 34.4% of the total workforce, supporting its development strategy and business layout[70] - The company is committed to enhancing its competitive advantage through continuous research and development efforts[35] - The company has developed core technologies for various medical devices, ensuring strong competitiveness and low risk of being replaced by competitors[49] - The company is focusing on expanding its product line with innovative technologies such as non-invasive hemodynamic monitoring and advanced imaging techniques[44] Product Development and Innovation - The company is actively developing new products, including wearable blood oxygen monitors and large self-service health check devices, to meet diverse market needs[37][39] - The company has established a comprehensive product system, mastering core technologies and production processes, with some products achieving industry-leading performance[33] - The company reported a comprehensive range of advanced medical diagnostic equipment, including full-digital B-type ultrasound diagnostic devices and automated biochemical analyzers, enhancing clinical diagnostic capabilities[42] - The company is focusing on expanding its product line, including new medical devices such as a pulse fetal heart rate monitor and a home oxygen machine, which were registered in early 2022[87] - The company plans to enhance its product line and expand its market channels by leveraging its cash flow and operational funds for R&D investments[80] Market Expansion and Sales Strategy - The company has expanded its market presence, selling products in over 150 countries and regions globally, enhancing its brand recognition[33] - The company is actively expanding its global market presence, contributing to the growth of overseas revenue and gaining international recognition[67] - The sales strategy includes a mix of distribution and direct sales, leveraging local distributors' resources to expand into overseas markets[62] - The company is focusing on optimizing production processes and enhancing automation to improve efficiency and product yield[97] - The company is committed to enhancing customer experience through improved service delivery and support for its medical devices[138] Compliance and Regulatory - The implementation of the EU's new medical device regulations (MDR and IVDR) has increased compliance costs and extended certification cycles for domestic manufacturers, but is expected to improve product quality in the long run[32] - The company has established a comprehensive quality management system and has passed ISO9001 and ISO13485 certifications, ensuring high consistency and reliability of its products[75] - The company has received CE certification for several new medical devices, including a fetal monitor and a pulse oximeter, enhancing its product portfolio for international markets[133] - The company has implemented a compliance management strategy for EU regulations, ensuring product compliance for market entry in the EU[103] Risks and Challenges - The company's overseas sales are primarily settled in USD, exposing it to exchange rate risks due to fluctuations in the RMB/USD exchange rate, which could impact pricing competitiveness and operating performance[199] - There is an increasing competition for talent in the medical device industry, particularly for core technology personnel, which could lead to instability in the talent pool if competitive compensation and incentives are not maintained[200] - Failure to retain core technical personnel may result in slowed or halted product development and potential technology leaks, adversely affecting the company's long-term growth[200]

Financial Performance - The company's revenue for Q1 2023 reached ¥368,699,882.77, representing a 101.21% increase compared to ¥183,239,114.02 in the same period last year[6] - Net profit attributable to shareholders was ¥170,052,052.02, up 131.97% from ¥73,307,986.92 year-on-year[6] - Basic earnings per share rose to ¥0.4232, reflecting a 131.89% increase from ¥0.1825 in the previous year[6] - Operating profit for the quarter was ¥188,205,059.30, up from ¥81,569,879.56, reflecting a growth of 130.5% year-over-year[23] - Net profit attributable to the parent company was ¥170,052,052.02, compared to ¥73,307,986.92 in Q1 2022, marking an increase of 132.5%[23] - The total comprehensive income for the quarter was ¥169,492,486.63, up from ¥72,474,343.11, an increase of 133.4% year-over-year[23] Cash Flow - The net cash flow from operating activities was ¥101,516,355.63, a significant increase of 185.55% compared to ¥35,551,530.90 in Q1 2022[6] - Total cash inflow from operating activities was ¥410,840,410.94, up from ¥220,255,932.02, indicating a growth of about 86% year-over-year[27] - Cash outflow from operating activities increased to ¥309,324,055.31 from ¥184,704,401.12, reflecting a rise of approximately 67%[27] - The net cash flow from investing activities was -¥159,393,812.47, compared to -¥27,462,747.05 in the previous year, showing a significant increase in cash outflow[27] - Cash inflow from financing activities totaled ¥322,376,199.40, while cash outflow was ¥533,152,263.57, resulting in a net cash flow of -¥210,776,064.17 for Q1 2023[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,686,584,058.64, a slight decrease of 1.24% from ¥3,732,805,832.45 at the end of the previous year[6] - Total liabilities decreased to ¥1,588,688,602.38 from ¥1,804,472,003.19, representing a decline of about 11.9%[20] - The company's equity attributable to shareholders increased by 8.79% to ¥2,097,895,456.26 from ¥1,928,333,829.26 at the end of the previous year[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,477[12] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[12] - The second-largest shareholder, Wang Guigang, owns 12.72% of the shares, amounting to 51,126,226 shares[12] Expenses - The company reported a significant increase in sales expenses, which rose by 258.01% to ¥34,329,659.15 due to higher platform and technical service fees[10] - The company experienced a 69.12% increase in tax liabilities, amounting to ¥60,207,358.78, driven by higher sales and profit levels[10] - Research and development expenses amounted to ¥25,005,015.83, which is an increase of 28.5% from ¥19,456,247.07 in the previous year[22] - Employee compensation payments rose to ¥59,520,945.56 from ¥42,830,540.37, reflecting an increase of approximately 39% year-over-year[27] Inventory and Receivables - The company reported accounts receivable of approximately ¥161.74 million, slightly up from ¥160.75 million at the beginning of the year[18] - Inventory at the end of the reporting period is approximately ¥514.44 million, an increase from ¥430.24 million at the beginning of the year[18] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the first quarter are approximately ¥1.13 billion, down from ¥1.39 billion at the beginning of the year[18] - The ending balance of cash and cash equivalents was ¥1,127,658,903.27, down from ¥1,387,323,098.06 at the beginning of the quarter, indicating a decrease of approximately 19%[28] Restricted Shares - The company has a total of 241,722,866 restricted shares, with 16,199,656 shares released during the period[16] - The company plans to unlock certain restricted shares based on executive lock-up conditions[15]

投资者关系活动记录表格式 证券代码：300869 证券简称：康泰医学 康泰医学系统（秦皇岛）股份有限公司 投资者关系活动记录表 编号：202105001 | --- | --- | --- | --- | |----------------|--------------------------------------|--------------------------------------------|-----------------------------------------------------------------| | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 | ☑ 业绩说明会 | | | | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 参与本次业绩说明会的投资者 | | | | 人员姓名 | | | | | 时间 | 2021 年 5 月 24 日 | 15：30-17：00 | | | 地点 | | 网络形式（全 ...

证券代码： 300869 证券简称：康泰医学 康泰医学系统(秦皇岛)股份有限公司 投资者关系活动记录表 编号：202205001 | --- | --- | --- | |-------------------------|---------------------------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 投资者网上提问 | | | 时间 | 2022 年 5 月 20 日 ( | 周五 ) 下午 15:30~16:30 | | 地点 | 采用网络远程的方式召开业绩说明会 | 公司通过全景网"投资者关系互动平台"（ https://ir.p5w.net ） | | 上市公司接待人 | 1 ...

证券代码： 300869 证券简称：康泰医学 康泰医学系统(秦皇岛)股份有限公司投资者关系活动记录 表 | --- | --- | --- | |-------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 投资者网上提问 | | | | | | | 时间 地点 | 2022 年 9 月 15 日 ( | 周四 ) 下午 15:30~16:30 公司通过全景网"投资者关系互动平台"（ https://ir.p5w.net ） | | 上市公司接待人 | ...

Financial Performance - Revenue for Q3 2022 was CNY 130,053,431.63, a decrease of 36.37% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 58,830,005.54, down 31.28% year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.1464, a decline of 31.29% compared to the previous year[5] - The company reported a 39.53% decline in net profit attributable to shareholders for the year-to-date, totaling CNY 174,206,387.64[5] - Total operating revenue for the current period was ¥462,183,267.50, a decrease of 35.7% compared to ¥719,299,418.51 in the previous period[18] - Net profit for the current period was ¥174,206,387.64, down 39.5% from ¥288,073,558.46 in the previous period[19] - Earnings per share (EPS) decreased to 0.4336 from 0.7170, representing a decline of 39.5%[19] - The company reported a total comprehensive income of ¥177,944,701.53, down from ¥287,990,743.62, a decrease of 38.3%[19] Assets and Liabilities - Total assets as of September 30, 2022, reached CNY 3,582,814,050.10, an increase of 28.46% from the end of the previous year[5] - The company's total assets as of September 30, 2022, amount to RMB 3,582,814,050.10, an increase from RMB 2,789,042,837.15 at the beginning of the year[14] - The company's total liabilities as of September 30, 2022, are RMB 1,643,481,979.88, compared to RMB 968,988,361.04 at the beginning of the year[14] - Total liabilities amounted to ¥1,643,481,979.88, up from ¥968,988,361.04, indicating a growth of 69.6%[16] - Total equity attributable to shareholders increased to ¥1,939,332,070.22 from ¥1,820,054,476.11, reflecting a growth of 6.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 67,069,817.19, a significant increase of 419.05%[5] - Cash flow from operating activities generated ¥67,069,817.19, a significant increase compared to ¥12,921,766.30 in the previous period[20] - The cash flow from investing activities resulted in a net outflow of ¥58,506,008.22, an improvement from a net outflow of ¥82,081,793.67 in the previous period[20] - The net cash flow from financing activities was approximately ¥794.91 million, compared to a negative net cash flow of ¥21.45 million in the previous period[21] - The total cash and cash equivalents at the end of the period reached ¥1.41 billion, an increase from ¥711.19 million at the end of the previous period[21] - The cash inflow from financing activities totaled approximately ¥1.68 billion, significantly higher than ¥837.65 million in the previous period[21] - Cash outflow for financing activities was approximately ¥882.55 million, compared to ¥859.09 million in the previous period[21] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥11.71 million, contrasting with a negative impact of ¥11.33 million in the previous period[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,621[10] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[10] - The company has no preferred shareholders as of the reporting period[10] Research and Development - Research and development expenses for the year-to-date were CNY 66,072,763.60, an increase of 46.12% compared to the same period last year[8] - Research and development expenses increased to ¥66,072,763.60 from ¥45,218,587.41, marking a rise of 46.1%[18] Inventory and Financing Activities - The company experienced a 90.98% decrease in cash paid for other financing activities, reflecting reduced cash used for pledged time deposits[9] - The company's inventory as of September 30, 2022, is RMB 470,620,021.65, up from RMB 418,692,933.45 at the beginning of the year[14] - The company reported a short-term loan of RMB 848,459,974.94 as of September 30, 2022, compared to RMB 800,394,398.44 at the beginning of the year[14] - The company issued 7,000,000 convertible bonds with a total fundraising amount of RMB 700,000,000, which were listed on July 20, 2022[12] - The company issued convertible bonds, raising CNY 700 million, contributing to a 126.68% increase in cash and cash equivalents[8] - Sales of goods and services received cash of CNY 489,260,746.50, a decrease of 35.26% year-on-year[9]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥332,129,835.87, a decrease of 35.50% compared to ¥514,897,348.56 in the same period last year[26]. - The net profit attributable to shareholders was ¥115,376,382.10, down 43.01% from ¥202,467,824.55 year-on-year[26]. - The basic earnings per share decreased to ¥0.29, a decline of 42.00% compared to ¥0.50 in the previous year[26]. - The net cash flow from operating activities was ¥36,807,967.46, a significant increase of 486.47% compared to a negative cash flow of -¥9,524,043.40 in the same period last year[26]. - The gross profit margin for the blood oxygen product line decreased by 7.31% to 39.30%, with revenue dropping by 45.32% year-on-year[107]. - The company reported a significant reduction in income tax expenses, down 58.53% to ¥14,202,067.09, attributed to decreased profits[106]. Assets and Investments - The total assets at the end of the reporting period were ¥2,891,649,095.09, reflecting a 3.68% increase from ¥2,789,042,837.15 at the end of the previous year[26]. - The net assets attributable to shareholders decreased slightly by 0.19% to ¥1,816,541,840.59 from ¥1,820,054,476.11 at the end of the previous year[26]. - The total amount of cash and cash equivalents decreased by 88.25% to ¥-24,903,112.27, reflecting a combination of factors from operating, investing, and financing activities[106]. - The company invested ¥46,149,562.82 during the reporting period, representing a 16.58% increase compared to ¥39,586,960.46 in the same period last year[114]. - The company has a total of ¥575,696,229.76 in cash and cash equivalents, accounting for 19.91% of total assets, down from 22.37% the previous year[108]. Research and Development - The company invested CNY 41.2744 million in R&D during the reporting period, representing a year-on-year increase of 42.71%[81]. - The R&D team comprises 498 personnel, accounting for 34.3% of the total workforce, emphasizing the importance of talent in driving innovation[80]. - The company has developed a range of innovative products, including non-invasive blood pressure simulators and dynamic electroencephalogram devices, enhancing its product portfolio[57]. - The company has established two subsidiaries in Changsha to strengthen its R&D capabilities, focusing on software and hardware development[81]. - The company plans to continue investing in its Changsha and Shenzhen subsidiaries to enhance R&D strength and maintain innovation capabilities[81]. Market Presence and Strategy - The company operates in the medical device industry, focusing on the research, production, and sales of medical diagnostic and monitoring equipment, with over 99.48% of revenue coming from its main business[38]. - The company has sold its products to over 150 countries and regions globally, demonstrating a strong international presence[38]. - The sales strategy includes a combination of direct sales and distribution, leveraging local distributors' resources to expand into overseas markets while also utilizing e-commerce platforms for direct sales[66]. - The company has established long-term relationships with hundreds of qualified suppliers, ensuring stable material procurement and production capabilities[65]. - The company has a complete industrial chain from mold making to product assembly, which supports its competitive edge in the medical device sector[78]. Product Development - The main product categories include blood oxygen, ECG, ultrasound, monitoring, blood pressure, and analysis testing devices, with a comprehensive range of offerings[39]. - The company has developed various types of blood oxygen devices, including fingertip, wrist, and desktop models, which support data storage and upload capabilities[39]. - The portable patient monitor can track vital signs for patients of all ages, including blood pressure and blood oxygen levels, enhancing patient care[46]. - The company has introduced a dynamic blood pressure monitor that supports multiple measurement modes and provides detailed analysis of blood pressure data[51]. - The automated biochemical analyzers help diagnose diseases by analyzing blood and other fluids, aiding in clinical evaluations[51]. Challenges and Risks - The company faces significant operational cost pressures due to rising logistics and labor costs, as well as substantial fluctuations in commodity prices, which could adversely affect profitability if macroeconomic conditions worsen[134]. - The medical device industry in China is experiencing intense competition, necessitating continuous technological innovation and accurate market demand understanding to capture market share[135]. - There is a potential for a significant decline in demand for pandemic-related products if the global pandemic is controlled, which may further impact the company's performance[136]. - The company is exposed to exchange rate risks, particularly with sales denominated in USD, and plans to adjust sales strategies and employ financial instruments to mitigate these risks[139]. Corporate Governance and Compliance - The company has not declared any cash dividends or stock bonuses for the half-year period, indicating a focus on reinvestment[147]. - The company remains committed to social responsibility, actively participating in various social initiatives while ensuring compliance with legal and ethical standards[151]. - The company reported no commitments from actual controllers, shareholders, related parties, acquirers, or other parties that were not fulfilled during the reporting period[154]. - The company had no violations regarding external guarantees during the reporting period[156]. - The semi-annual financial report was not audited[157]. Shareholding Structure - The total number of shares before the change was 401,796,800, with 61.84% being restricted shares, which decreased by 6,734,249 to 241,722,866, now representing 60.16%[183]. - The unrestricted shares increased by 6,734,249, bringing the total to 160,073,934, which is now 39.84% of the total shares[183]. - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252, with no changes during the reporting period[187]. - The total number of common stock shareholders at the end of the reporting period was 44,388[187]. - The overall shareholding structure remains stable, with no significant changes in the ownership dynamics of the top shareholders[200].